Literature DB >> 31077138

The changing faces of migraine.

Paolo Martelletti1, Messoud Ashina2, Lars Edvinsson3.   

Abstract

Entities:  

Year:  2019        PMID: 31077138      PMCID: PMC6734366          DOI: 10.1186/s10194-019-1006-z

Source DB:  PubMed          Journal:  J Headache Pain        ISSN: 1129-2369            Impact factor:   7.277


× No keyword cloud information.
Migraine represents today the crossroads of several scientific evidences, such as lofty planetary prevalence, serious disability, damaged quality of life, reduced productive capacity, costly healthcare resulting in a creeping sentiment of social stigma [1-3]. From the same crossroads, the migraine paradigm as a multimorbid disease flows out [4]: perhaps multi-systemic, however to be scanned and evaluated at a distance as the horizon, in order to avoid the risk of parcelling its real extent. From before the triptans era, in less than 30 years we have passed from the common acceptance of migraine as an ineluctable family heredity to the evidence of a complex genetic trait involving genomics, metabolomics and, perhaps in the near future, also proteomics [5, 6]. In the meantime, the awareness of migraine as real disease has been widespread in the general population and even physicians’ education on migraine has made giant steps forward at different levels of research, professionalism and safe prescription [7-10]. Now that we are facing a new era, the Calcitonin Gene Related Peptide (CGRP) one, with new perspectives and hopes that only a new pharmacological class dedicated to the prevention of migraine can offer, we must not forget what has made this possible: solid and undisputable scientific evidences acquired over the years first on animal and then on human models [11, 12]. This topical collection helps us to orient the readership in the great mass of data that emerge from literature and systematize them in a series of comprehensive reviews, progressively centered on chained topics. From the classic burden of disease to the new acquisitions of genetics, from the new pathophysiology CGRP-centered of migraine to the description of the various new molecules and their correct and safe therapeutic application, up to the rocks of refractoriness and the unavoidable ethical and economic need to identify the right patient for the right drug using the precision medicine [13, 14]. Satisfied all the parameters, before the end of this path we could have the chance to mark out the vanishing point of migraine and to score the greatest try to be devoted to each migraine patient.
  11 in total

Review 1.  The Global Burden of Headache.

Authors:  Deanna Saylor; Timothy J Steiner
Journal:  Semin Neurol       Date:  2018-05-23       Impact factor: 3.420

2.  A Licence to Prescribe.

Authors:  Cornelis Kramers; Ben J Janssen; Wilma Knol; Marleen H M Hessel; Wilhelmina M Mulder; Glenn Dumont; Antoinette Maassen van den Brink; Jelle Tichelaar
Journal:  Br J Clin Pharmacol       Date:  2017-03-02       Impact factor: 4.335

Review 3.  Tailoring Treatment in Polymorbid Migraine Patients through Personalized Medicine.

Authors:  Leda Marina Pomes; Giovanna Gentile; Maurizio Simmaco; Marina Borro; Paolo Martelletti
Journal:  CNS Drugs       Date:  2018-06       Impact factor: 5.749

4.  Migraine disability complicated by medication overuse.

Authors:  P Martelletti
Journal:  Eur J Neurol       Date:  2018-08-01       Impact factor: 6.089

Review 5.  Migrainomics - identifying brain and genetic markers of migraine.

Authors:  Dale R Nyholt; David Borsook; Lyn R Griffiths
Journal:  Nat Rev Neurol       Date:  2017-11-17       Impact factor: 42.937

Review 6.  Migraine: Stigma in Society.

Authors:  Simy K Parikh; William B Young
Journal:  Curr Pain Headache Rep       Date:  2019-02-09

7.  Role of CGRP in Migraine.

Authors:  Lars Edvinsson
Journal:  Handb Exp Pharmacol       Date:  2019

8.  CGRP in Human Models of Migraine.

Authors:  Håkan Ashina; Henrik Winther Schytz; Messoud Ashina
Journal:  Handb Exp Pharmacol       Date:  2019

9.  Multimorbidity in patients with chronic migraine and medication overuse headache.

Authors:  Domenico D'Amico; Emanuela Sansone; Licia Grazzi; Ambra M Giovannetti; Matilde Leonardi; Silvia Schiavolin; Alberto Raggi
Journal:  Acta Neurol Scand       Date:  2018-09-03       Impact factor: 3.209

Review 10.  The omics in migraine.

Authors:  Luana Lionetto; Giovanna Gentile; Elisa Bellei; Matilde Capi; Donata Sabato; Francesco Marsibilio; Maurizio Simmaco; Luigi Alberto Pini; Paolo Martelletti
Journal:  J Headache Pain       Date:  2013-07-01       Impact factor: 7.277

View more
  1 in total

1.  Burden and attitude to resistant and refractory migraine: a survey from the European Headache Federation with the endorsement of the European Migraine & Headache Alliance.

Authors:  Simona Sacco; Christian Lampl; Antoinette Maassen van den Brink; Valeria Caponnetto; Mark Braschinsky; Anne Ducros; Patrick Little; Patricia Pozo-Rosich; Uwe Reuter; Elena Ruiz de la Torre; Margarita Sanchez Del Rio; Alexandra J Sinclair; Paolo Martelletti; Zaza Katsarava
Journal:  J Headache Pain       Date:  2021-05-18       Impact factor: 7.277

  1 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.